Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Famotidine Launch, Perrigo Persists With In-House Prowess

This article was originally published in The Tan Sheet

Executive Summary

Perrigo's promotional packaging, labeling expertise and distribution processes are "critical" to leading the private-label market, according to Chief Financial Officer Judy Brown

You may also be interested in...

Perrigo Reaches Record As Retailers, Consumers Turn More To Store Brands

Current challenging economic conditions may help Perrigo's private label business grow, unlike the sales slumps that commonly hit consumer product companies when spending slows

Private-Label Momentum Grows With Mass Retailers’ Low-Price Programs

The private-label sector, already growing as consumers react to a weak economy, received a boost when mass-market retailers Wal-Mart and Target added nonprescription drugs to low-price pharmacy programs

FLAVORx Hopes A Spray-Full Of Pill Glide Helps The Medicine Go Down

FLAVORx designed its flavored Pill Glide Swallowing Sprayto help consumers take difficult-to-swallow or unpleasant-tasting pills





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts